

EHA 2025 Congress

June 12–15, 2025
Milan, Italy



 **MultipleMyelomaHub**

TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma.

EHA 2025: Top abstracts in MM

June 12–15, 2025

Newly diagnosed multiple myeloma			
Abstract	Title	Speaker	Date and time (CEST)
S185 View	Integrative multiomic analysis of multiple myeloma identifies molecular predictors of MRD in the MIDAS trial	Stéphane Minvielle	Thursday, June 12 17:00–17:15
S186 View	Multiomics characterization of minimal residual disease (MRD) kinetics in multiple myeloma (MM) patients reveals that early immunotherapy interception drives clinical benefit in experimental models	Noelia Collado-Gisbert	Thursday, June 12 17:15–17:30
S194 View	Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplant: Long-term follow-up of the randomised, phase 2 FORTE trial	Francesca Gay	Thursday, June 12 18:00–18:15
S199 View	Circulating tumor cells for the staging of multiple myeloma: A European pooled analysis of 2446 newly diagnosed patients	Luca Bertamini	Friday, June 13 18:00–18:15
PF733 View	Extended dosing schedule of belantamab mafodotin in combination with daratumumab, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma: The phase 1/2 BelaDRd study	Evangelos Terpos	Friday, June 13 18:30
PS1711 View	Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FASTCAR-T (GC012F/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma	Juan Du	Saturday, June 14 18:30
PS1763 View	Health-related quality of life in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma (MM) in the phase 3 CEPHEUS trial	Vania Hungria	Saturday, June 14 18:30
S205 View	Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trial	Aurore Perrot	Sunday, June 15 11:00–11:15
S206 View	Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1	Meletios A. Dimopoulos	Sunday, June 15 11:15–11:30

Newly diagnosed multiple myeloma (continued)			
Abstract	Title	Speaker	Date and time (CEST)
S207 View	A randomized, multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) for the treatment of patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial	C. Ola Landgren	Sunday, June 15 11:30–11:45
S208 View	Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III ISKIA trial)	Francesca Gay	Sunday, June 15 11:45–12:00
S209 View	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRD) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial	Lisa Leypoldt	Sunday, June 15 12:00–12:15

Relapsed/refractory multiple myeloma			
Abstract	Title	Speaker	Date and time (CEST)
S192 View	Long-term (≥ 5 year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma	Sundar Jagannath	Thursday, June 12 17:30–17:45
PF728 View	Updated results from phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma	Meletios A. Dimopoulos	Friday, June 13, 18:30
S100 View	First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody, in patients with relapsed/refractory multiple myeloma: Initial phase 1 results	Rakesh Popat	Saturday, June 14, 11:45–12:00
S200 View	Talquetamab + cetrelimab in patients with relapsed/refractory multiple myeloma: Initial safety and efficacy results from the phase 1b TRIMM-3 study	Aurore Perrot	Saturday, June 14, 17:00–17:15
S201 View	Phase 2 registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): Updated results from IMAGINE-1	Gurbakhash Kaur	Saturday, June 14, 17:15–17:30
S202 View	Linvoseltamab + carfilzomib in patients with relapsed/refractory multiple myeloma: Initial results from the LINKER-MM2 trial	Salomon Manier	Saturday, June 14, 17:30–17:45

Relapsed/refractory multiple myeloma (continued)			
Abstract	Title	Speaker	Date and time (CEST)
S203 View	Isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma: The randomized phase 3 IRAKLIA study	Xavier Leleu	Saturday, June 14, 17:45–18:00
S204 View	Daratumumab or observation for minimal residual disease reappearance in multiple myeloma: Results from the PREDATOR-MRD randomized trial	Krzysztof Jamrozak	Saturday, June 14, 18:00–18:15
PS1727 View	Mezigdomide (MEZI) in novel combinations for relapsed or refractory multiple myeloma (RRMM): Updated results from the CA057-003 trial	Fredrik Schjesvold	Saturday, June 14, 18:30
PS1728 View	Absolute lymphocyte count as a key biomarker for monitoring safety after ciltacabtagene autoleucel	Yi Lin	Saturday, June 14, 18:30
PS1736 View	Talquetamab vs real-world physician's choice in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen therapy: Updated analyses of MonumentAL-1 vs LocoMMotion/MoMMent	María-Victoria Mateos	Saturday, June 14, 18:30
PS1764 View	Outpatient step-up dosing and safety with talquetamab: A real-world Mayo clinic study	Shaji Kumar	Saturday, June 14, 18:30
LB4001 View	Phase 2 study of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: RedirecTT-1	Shaji Kumar	Sunday, 15 June, 09:15–09:30

Other plasma cell dyscrasias			
Abstract	Title	Speaker	Date and time (CEST)
S195 View	The evaluation of circulating tumor cells as a prognostic biomarker in newly diagnosed light chain amyloidosis	Ioannis Kostopoulos	Friday, June 13, 17:00–17:15
S197 View	Multiomic characterization of clonotypic B cells in patients (pts) with light-chain amyloidosis (AL) and multiple myeloma (MM)	Carmen Gonzalez	Friday, June 13, 17:30–17:45
S198 View	Identifying an ultra-poor risk 'Mayo stage IIIC' group in systemic AL amyloidosis in the daratumumab-era: A European collaboration	Jahanzaib Khwaja	Friday, June 13, 17:45–18:00
PS1748 View	Increased risk of infections in individuals with smoldering multiple myeloma: Results from the screened iStopMM study	Lærke Sloth Andersen	Saturday, June 14, 18:30



#EHA2025

Follow us on X to keep up to date
with the latest from the congress

@MM_Hub

 **MultipleMyelomaHub**

Brought to you by

